HRS-4642 with Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
This study is a single-arm phase II clinical study to include 32 patients with advanced pancreatic cancer with KRAS G12D mutation to evaluate the effectiveness of HRS-4642 combined with nitutuzumab and AG for first-line treatment of advanced pancreatic cancer.
Metastatic Pancreatic Carcinoma
DRUG: HRS-4642|DRUG: Nimotuzumab|DRUG: gemcitabine + nab-paclitaxel
Objective reponse rate (ORR), The proportion of patients who had tumor evaluated as PR according to RECIST1.1 criteria during the whole study, Up to 2 years
Duration of remission （DoR）, The time from the first assessment of the tumor as CR or PR to the first assessment of PD or death from any cause during the whole study., Up to 2 years|Disease control rate (DCR), The proportion of patients who had tumor evaluated as PR or SD according to RECIST1.1 criteria during the whole study., Up to 2 years|Progression-free survival （PFS）, The time from enrolled to disease pregression or death from any cause during the whole study., Up to 2 years|Overall survival (OS), The time from enrolled to death from any cause during the whole study., Up to 2 years
This study used a Simon two-stage design, with at least 15 subjects enrolled in the first stage. During this period, after 6-9 subjects complete the first cycle of treatment, the existing safety data shall be summarized and analyzed to integrate the safety results to assess the tolerance. If tolerated, the proposed dose, other dose level or dosage regimen shall be discussed by investigators. As with\> 5 achieved remission (CR / PR), enrollment continued to 32; if 5 were remitted, the SMC assessed assessed and decided. The study process included screening, treatment and follow-up periods (safety and survival follow-up after termination of study treatment).